This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: April 30th, 2009 - April 30th, 2010

This activity is no longer available for credit, however its content is still relevant for your educational needs.

Target Audience
This activity was developed for pharmacy directors, P&T Committee members, managed care pharmacists, oncology pharmacists, and other key stakeholders who wish to enhance their knowledge concerning the implementation of a value-based benefit design for cancer care.

Learning Objectives
At the completion of this activity participants should be able to:

• Identify the intersection of epidemiological shifts in the American colorectal cancer patient population, new colorectal cancer drug costs, and new diagnostic measures, on achieving value-based clinical treatment for this condition
• Define the role of value (cost, quality, access) in the new value-based healthcare system and the incentives of payers and purchasers to meet each of these 3 aspects of value in cancer care
• Explain how the NCCN clinical practice treatment guidelines are aiding stakeholders in attaining value-based cancer care amidst rising new product costs
• Incorporate value-based care in the treatment of colorectal cancer

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc. have no financial relationships to disclose. The associates of Center of Excellence Media, LLC, have no financial relationships to disclose.

Faculty Disclosures
Gary M. Owens, MD, is a Consultant to Asthmatx, Biosense Webster, Centocor-OrthoBiotech, Eli Lilly, Genentech, and Novartis.

John Fox, MD, MHA has nothing to disclose.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.